Perspective Therapeutics (CATX) Gross Margin Growth (5y) (2015 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) Gross Margin Growth (5y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -3,938.00 |
| Sep 30, 2023 | 23.00 |
| Jun 30, 2023 | -1,576.00 |
| Mar 31, 2023 | -1,511.00 |
| Sep 30, 2022 | 1,711.00 |
| Jun 30, 2022 | 736.00 |
| Mar 31, 2022 | 2,666.00 |
| Dec 31, 2021 | 4,342.00 |
| Sep 30, 2021 | 3,569.00 |
| Jun 30, 2021 | 5,395.00 |
| Mar 31, 2021 | 4,688.00 |
| Dec 31, 2020 | 4,695.00 |
| Sep 30, 2020 | 4,568.00 |
| Jun 30, 2020 | 3,171.00 |
| Mar 31, 2020 | 5,447.00 |
| Dec 31, 2019 | 5,393.00 |
| Sep 30, 2019 | 5,865.00 |
| Jun 30, 2019 | 6,003.00 |
| Mar 31, 2019 | 4,120.00 |
| Dec 31, 2018 | 4,330.00 |